What you are saying is correct. For those that have Pharma business experience, the 2017 SequestOx-II situation is vastly different than the 2016 SequestOx-I situation.
To continue to reference NH 2016 comments for SequestOx-I, in May 2017 as applicable to SequestOx-II, is simply misinformation.